MiNK Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that MiNK Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($2.89M) | Nov 14, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($4.24M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($4.24M) | Aug 14, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($2.77M) | Nov 14, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($2.77M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($2.77M) | May 15, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($1.81M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($2.70M) | Aug 14, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($2.70M) | Nov 14, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($3.81M) | Nov 14, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($3.81M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($3.81M) | May 15, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($5.12M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($6.20M) | Aug 13, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($6.20M) | Nov 14, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($5.69M) | Nov 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($5.69M) | May 14, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($5.69M) | Aug 13, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($6.33M) | Nov 14, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($6.11M) | Nov 14, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($3.18M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($4.05M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($2.70M) | May 15, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($1.88M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($3.07M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($3.83M) | May 15, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($5.22M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($6.34M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($5.85M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($7.99M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($7.70M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($7.37M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($13.38M) | Nov 3, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($5.61M) | Aug 15, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($3.01M) | May 13, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($5.92M) | Nov 29, 2021 |